RETA Stock News

Bardoxolone's Complete Response Letter caused the stock to lose much of its share price last year. The other lead medicine (omaveloxolone) is going to the FDA for Friedrich's Ataxia approval this Febr

Reata Pharmaceuticals has an FDA decision (PDUFA) date of February 28 for omaveloxolone. Bardoxolone is in three Phase 3 trials for different types of polycystic kidney disease.

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Goldman Sachs boosted the price target on Reata Pharmaceuticals, Inc. (NASDAQ: RETA) from $86 to $115. Goldman Sachs analyst Madhu Kumar maintained the stock with a Buy rating. Reata Pharmaceuticals

Over the past 3 months, 5 analysts have published their opinion on Reata Pharmaceuticals (NASDAQ:RETA) stock. These analysts are typically employed by large Wall Street banks and tasked with understan

Reata (RETA) reports a narrower-than-expected loss in the third quarter. Stock rises after RETA states that the FDA did not request additional data on the NDA for omaveloxolone in Friedreich's ataxia.

Raymond James raised the price target on Planet Fitness, Inc. (NYSE: PLNT) from $70 to $84. Raymond James analyst Joseph Altobello maintained a Strong Buy rating on the stock. Planet Fitness shares

Reata (RETA) reports a narrower-than-expected loss in the third quarter. Stock rises after RETA states that the FDA did not request additional data on the NDA for omaveloxolone in Friedreich's ataxia.

Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday. TaskUs, Inc. (NAS

U.S. stocks closed higher on Tuesday, with the Dow Jones surging more than 300 points. Here is the list of some big stocks recording gains in the previous session. TaskUs, Inc. (NASDAQ: TASK) shares

Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast ca

Reata Pharmaceuticals, Inc. (NASDAQ:RETA ) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET Company Participants Warren Huff - Chief Executive Officer Manmeet Soni - President Colin Meyer -

Investors are cheering the company's third-quarter update.

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 8.09% and 62.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th

Investors are cheering the company's third-quarter update.